Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer

• Published in: Cancer prevention research (Philadelphia, Pa.) Vol. 5; no. 2; pp. 248 - 259
• Main Authors: Lu, Yan, Liu, Pengyuan, Van den Bergh, Francoise, Zellmer, Victoria, James, Michael, Wen, Weidong, Grubbs, Clinton J, Lubet, Ronald A, You, Ming
• Format: Journal Article
• Language: English
• Published: United States 01.02.2012
• Subjects: Animals; Antineoplastic Agents - pharmacology; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Blotting, Western; Cell Cycle - drug effects; Cell Proliferation - drug effects; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; MicroRNAs - genetics; Oligonucleotide Array Sequence Analysis; Quinazolines - pharmacology; Rats; Rats, Inbred F344; Real-Time Polymerase Chain Reaction; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Receptor, Epidermal Growth Factor - metabolism; RNA, Messenger - genetics; Signal Transduction - drug effects; Urinary Bladder Neoplasms - chemically induced; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - genetics

The epidermal growth factor receptor inhibitor Iressa has shown strong preventive efficacy in the N-butyl-N-(4-hydroxybutyl)-nitrosamine (OH-BBN) model of bladder cancer in the rat. To explore its antitumor mechanism, we implemented a systems biology approach to characterize gene expression and sign...